MedTrace Logo

The Effect of Magnesium Oxide on Plasma Phosphate in Hemodialysis Patients

NCT01854437 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 42

Last updated 2013-05-15

No results posted yet for this study

Summary

Hyperphosphatemia is a common problem in hemodialysis (HD) patients. Different chelators for control of Hyperphosphatemia are used. The aim of this study was to assess the effect of magnesium oxide (Mg Oxide) on the control of serum phosphorus (P) level and evaluation of its side effects in hemodialysis patients.

Conditions

  • Hyperphosphatemia

Interventions

DRUG

Mg Oxide

250 mg orally for 4 weeks

Sponsors & Collaborators

  • Shiraz University of Medical Sciences

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01854437 on ClinicalTrials.gov